Bank of America reports 5.1% stake in Mereo BioPharma (MREO)

Rhea-AI Filing Summary

Mereo BioPharma Group plc ownership filing shows Bank of America Corporation reports beneficial ownership of 40,976,460 ordinary shares, representing 5.1% of the class. The calculation cites 798,078,829 shares outstanding as of March 18, 2026 from the issuer's Form 10-K. The filing states that the reported holdings reflect shared voting and dispositive power across Bank of America and certain wholly owned subsidiaries.

Key Figures

Beneficial ownership: 40,976,460 shares Percent of class: 5.1% Shares outstanding (context): 798,078,829 shares

3 metrics

Beneficial ownership 40,976,460 shares Amount reported by Bank of America on Schedule 13G

Percent of class 5.1% Percent of ordinary shares based on cited outstanding share count

Shares outstanding (context) 798,078,829 shares Shares outstanding cited from issuer Form 10-K as of March 18, 2026

Key Terms

Schedule 13G, Beneficial ownership, Shared voting power, CUSIP

4 terms

Schedule 13G regulatory

"Item 2. | (a) | Name of person filing: BANK OF AMERICA CORP /DE/"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership financial

"Item 4. | Ownership (a) | Amount beneficially owned: 40,976,460.00"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Shared voting power corporate governance

"Item 4. | (ii) Shared power to vote or to direct the vote: 40,976,460.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

CUSIP market

"Item 2. | (e) | CUSIP Number(s): G6014T100"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Mereo BioPharma Group plc

(Name of Issuer)

Ordinary shares

(Title of Class of Securities)

G6014T100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G6014T100

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 40,976,460.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 40,976,460.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

40,976,460.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: "1. The security CUSIP corresponds to Mereo Biopharma Group PLC CUSIP International Numbering System (CINS) of the common stock. 2. The beneficial ownership calculation relies on the 798,078,829 outstanding shares disclosed in the Form 10-K by the issuer on March 19, 2026, which reports share totals as of March 18, 2026."

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Mereo BioPharma Group plc
(b)	Address of issuer's principal executive offices: ONE CAVENDISH PLACE, FOURTH FLOOR, LONDON, UNITED KINGDOM, W1G 0QF.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Ordinary shares
(e)	CUSIP Number(s): G6014T100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 40,976,460.00
(b)	Percent of class: 5.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 40,976,460.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 40,976,460.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); and Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Monica Yako
Name/Title:	Authorized Signatory
Date:	05/14/2026

FAQ

What stake does Bank of America report in Mereo BioPharma (MREO)?

Bank of America reports beneficial ownership of 40,976,460 shares (5.1%). This percentage is based on 798,078,829 shares outstanding as of March 18, 2026, per the filing's cited Form 10-K reference.

Does Bank of America claim sole voting power over MREO shares?

No. The filing shows 0 sole voting power and 40,976,460 shared voting power. The shares are reported as held with shared voting and dispositive authority across subsidiaries.

Which Bank of America entities are involved in the Schedule 13G filing?

The filing is made by Bank of America Corporation on behalf of itself and subsidiaries including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International, as stated in the filing.

What outstanding share count does the filing use to calculate percent ownership?

The filing relies on 798,078,829 shares outstanding disclosed in Mereo's Form 10-K, with the share totals reported as of March 18, 2026, per the filing comment.

Is the reported ownership majority, and does it imply control of MREO?

No. The reported 5.1% stake is a minority position. The filing shows shared voting and dispositive power, not sole control or majority ownership.